Aaron S. Gal and Sanford - Free people check

(1 - 10 from 19

)

Allergan to Buy LifeCell for $2.9 Billion (AGN) | Investopedia

www.investopedia.com

Following the deal announcement, Sanford C. Bernstein & Company analyst Aaron Gal said he sees the acquisition as synergistic and feels it was completed at a reasonable price. The analyst reiterated his "outperform" rating and $275 per share price. Additionally, Deutsche Bank maintained its coverage ...

And Now, Gastric Surgery for Kids - Bloomberg

www.bloomberg.com

Sanford C. Bernstein analyst Aaron Gal says approval for children could increase Lap-Band sales by as much as $20 million a year.

Biologic Drugs, Biosimilars, and Barriers to Entry - Semantic Scholar

pdfs.semanticscholar.org

http://www.ftc.gov/system/files/documents/public_events/Follow-. On% 20Biologics%20Workshop%3A%20Impact%20of%20Recent%20Legis lative% 20and%20Regulatory%20Naming%20Proposals%20on%20Compet ition/purvis. pdf (last visited Sept. 21, 2014) Aaron Gal, Senior Analyst, Sanford C. Bernstein & Co., ...

Sanford C. Bernstein & Co., LLC., Research Division: Private ...

www.bloomberg.com

... for Sanford C. Bernstein & Co., LLC., Research Division. Mr. Colin A. McGranahan. United States Director of Research. Mr. Inigo Fraser-Jenkins. Head of Global Quantitative and European Equity Strategy and Senior Analyst. Dr. Noah Yaakov Weisberger Ph.D. Managing Director and Senior Analyst. Dr. Aaron Gal Ph.D.

FDA panel recommends approval for Actavis' antibiotic drug – FnB ...

fnb.pe

The panel, however, raised concerns around labeling,particularly for patients with renal impairment, SanfordBernstein & Co analyst Aaron Gal wrote in a note. The committee also voted not to recommend the drug's use intreating hospital- acquired bacterial pneumonia (HABP) andbacteremia, citing inadequate evidence.

The Latest On Biosimilars - Biosimilar Development

www.biosimilardevelopment.com

Richard Mark Kirkner for Drug Topics put together a great article, interviewing Aaron Gal, PhD., Sanford C. Bernstein & Co., on the forces at play on the biosimilar market. A couple of snippets for you: Gal noted another positive sign for acceptance of biosimilars in the E.U. 'Each successive product in the European Union did ...

U.K. Now Treats Chronic Migraines with Botox - Dr. Clayton Frenzel ...

www.advancedcosmeticsurg.com

Migraine Action says one in seven people in the UK suffer from migraine, affecting twice as many women as men. The U.S.'s Food and Drug Administration is likely to decide this month whether the product can be sold for migraines, Aaron Gal, a Sanford C. Bernstein & Co. analyst in New York, said in May.

Person "Gal" (1)
Forename "Aaron" (33801)
Name "Gal" (2817)

sorted by relevance / date

Advanced Search

Search name: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Aaron S. Gal and Sanford Free People Check

Allergan to Buy LifeCell for $2.9 Billion (AGN) | Investopedia

And Now, Gastric Surgery for Kids - Bloomberg

Biologic Drugs, Biosimilars, and Barriers to Entry - Semantic Scholar

Sanford C. Bernstein & Co., LLC., Research Division: Private ...

FDA panel recommends approval for Actavis' antibiotic drug – FnB ...

The Latest On Biosimilars - Biosimilar Development

U.K. Now Treats Chronic Migraines with Botox - Dr. Clayton Frenzel ...

Aaron Gal, Sanford C. Bernstein Analyst Profile | Invesd

Actavis Management Discusses Q Results - Earnings Call...

Forest Laboratories Management Discusses Q Results - Earnings...

All web results to the name "Aaron S. Gal"